<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595684</url>
  </required_header>
  <id_info>
    <org_study_id>TADALAFIL-OB</org_study_id>
    <nct_id>NCT02595684</nct_id>
  </id_info>
  <brief_title>Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.</brief_title>
  <official_title>Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is a chronic disease of multifactorial etiology that develops from the interaction of&#xD;
      the influence of nutritive , metabolic , cellular and molecular psychological factors.&#xD;
&#xD;
      Tadalafil is Is a drug inhibiting the enzyme phosphodiesterase-5 (PDE-5), responsible for&#xD;
      inactivating the vasodilator nitric oxide. USING paragraph was mainly treat erectile&#xD;
      dysfunction, and recently approved for the treatment of pulmonary hypertension , it is&#xD;
      innovative because of its longer life means, provides efficacy after 36 hours and the highest&#xD;
      selectivity.&#xD;
&#xD;
      The aim of this study is to evaluate the effect of tadalafil on insulin sensitivity and&#xD;
      insulin secretion in obese men.&#xD;
&#xD;
      The investigators hypothesis is that the administration of tadalafil improve the insulin&#xD;
      sensitivity and insulin secretion in obese men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled clinical trial in 18 men aged between 30 and&#xD;
      50 years with obesity (BMI 30-39.9) according to the World Health Organization (WHO) criteria&#xD;
      without treatment.&#xD;
&#xD;
      They will be assigned randomly in two groups of 9 patients, each to receive 5 mg of tadalafil&#xD;
      or placebo every day at night during 28 days.&#xD;
&#xD;
      There will be evaluated Insulin secretion, both first phase of insulin secretion by Stumvoll&#xD;
      Inex as well as Total Insulin Secretion by Area Under the Curve of glucose and insulin and&#xD;
      Insulinogenic Index, and Insulin sensitivity by Matsuda index.&#xD;
&#xD;
      Waist circumference, glucose and insulin levels, lipid profile and blood pressure are going&#xD;
      to be load will be evaluated before and after intervention in both groups.&#xD;
&#xD;
      Statistical analysis will be presented through measures of central tendency and dispersion,&#xD;
      average and deviation standard for quantitative variables; frequencies and percentages for&#xD;
      variable qualitative. Qualitative variables will be analyzed by X2, will be used for&#xD;
      differences inter-group Mann-Whitney U Test and Wilcoxon Test for the within-groups&#xD;
      differences. Will be considered statistical significance p ≤0.05.&#xD;
&#xD;
      This protocol was approved by a local Ethics Committee and written informed consent will be&#xD;
      obtained from all volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>Fasting glucose at Day 28</time_frame>
    <description>Fasting glucose will be evaluated at baseline and Day 28 with enzymatic-colorimetric.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial Glucose</measure>
    <time_frame>Postprandial glucose at Day 28</time_frame>
    <description>Postprandial glucose will be evaluated at baseline and Day 28 after a oral glucose. tolerance test with enzymatic-colorimetric techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First Phase of Insulin Secretion</measure>
    <time_frame>First phase of insulin secretion at Day 28</time_frame>
    <description>First phase of insulin secretion will be calculated at baseline and Day 28 with Stumvoll Index.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Insulin Secretion</measure>
    <time_frame>Total insulin secretion at Day 28</time_frame>
    <description>Total insulin secretion will be calculated at baseline and Day 28 with Insulinogenic Index.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>Insulin sensitivity at Day 28</time_frame>
    <description>Insulin sensitivity will be calculated at baseline and Day 28 with Matsuda Index.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) Glucose</measure>
    <time_frame>AUC at Day 28</time_frame>
    <description>Area under the curve of glucose measured at baseline and Day 28. The area under the curve (AUC) of glucose, (0.5 * glucose (G) 0´ + (G 30´+G 60´ + G 90´) + 0.5 * G 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) Insulin</measure>
    <time_frame>AUC at Day 28</time_frame>
    <description>Area under the curve of insulin measured at baseline and Day 28. The Area Under the Curve (AUC) of insulin, (0.5 * Insulin (I) 0´ + (I 30´+I 60´ + I 90´) + 0.5 * I 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Body Weight at Day 28</time_frame>
    <description>The body weight will be measured at baseline and Day 28 by Electrical bioimpedance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Body Mass Index at Day 28</time_frame>
    <description>The Body Mass Index will be measured at baseline and Day 28 by Quetelet Index Formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>Waist circumference at Day 28</time_frame>
    <description>Waist circumference was evaluated at baseline and at Day 28 with a flexible tape.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Triglycerides levels at Day 28</time_frame>
    <description>Triglycerides levels will be evaluated at baseline and Day 28 with enzymatic-colorimetric techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Total cholesterol levels at Day 28</time_frame>
    <description>Total cholesterol levels will be evaluated at baseline and Day 28 with enzymatic-colorimetric techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein Cholesterol (HDL-c)</measure>
    <time_frame>HDL-c levels at Day 28</time_frame>
    <description>High density lipoprotein cholesterol (HDL-c) levels will be evaluated at baseline and Day 28 with enzymatic-colorimetric techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein Cholesterol (LDL-c)</measure>
    <time_frame>LDL-c levels at Day 28</time_frame>
    <description>Low density lipoprotein cholesterol (LDL-c) levels will be evaluated at baseline and Day 28 with Friedewald formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Systolic Blood Pressure at Day 28</time_frame>
    <description>The systolic blood pressure was evaluated at baseline and Day 28 with a digital sphygmomanometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Diastolic Blood Pressure at Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Fat</measure>
    <time_frame>Body fat at Day 28</time_frame>
    <description>The body fat will be measured at baseline and Day 28 by Electrical bioimpedance in %</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tadalafil capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcined magnesia capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
    <arm_group_label>Tadalafil</arm_group_label>
    <other_name>Tadalafilo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Calcined magnesia capsules: one per day, at night, during 28 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men&#xD;
&#xD;
          -  Age: 30-50 years&#xD;
&#xD;
          -  BMI: 30 to 39.9 kg/m²&#xD;
&#xD;
          -  No Pharmacotherapy during the last 3 months&#xD;
&#xD;
          -  Signature Consent under Information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cholesterol: ≥ 240 mg / dl&#xD;
&#xD;
          -  Triglycerides: ≥ 400 mg / dl&#xD;
&#xD;
          -  Fasting glucose: ≥ 126 mg / dl&#xD;
&#xD;
          -  Diabetes mellitus.&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Patients with renal, liver and / or thyroid disease&#xD;
&#xD;
          -  Consumption of drugs with known effects on glucose or insulin metabolism.&#xD;
&#xD;
          -  Use of cigar and / or drugs&#xD;
&#xD;
          -  Hypersensitivity to tadalafil&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel González-Ortíz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Terapéutica Experimental y Clínica</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2020</results_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Manuel González Ortiz</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Tadalfil</keyword>
  <keyword>Insulin secretion</keyword>
  <keyword>Insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tadalafil</title>
          <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tadalafil</title>
          <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" spread="7.9"/>
                    <measurement group_id="B2" value="38.4" spread="6.4"/>
                    <measurement group_id="B3" value="39.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="0.4"/>
                    <measurement group_id="B2" value="4.8" spread="0.7"/>
                    <measurement group_id="B3" value="4.85" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Postprandial Glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" spread="1.9"/>
                    <measurement group_id="B2" value="5.4" spread="1.3"/>
                    <measurement group_id="B3" value="6" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>First Phase of Insulin</title>
          <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1332" spread="487"/>
                    <measurement group_id="B2" value="1135" spread="598"/>
                    <measurement group_id="B3" value="1233.5" spread="542.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Insulin Secretion</title>
          <description>The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.82" spread="0.45"/>
                    <measurement group_id="B2" value="0.45" spread="0.21"/>
                    <measurement group_id="B3" value="0.64" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="1.2"/>
                    <measurement group_id="B2" value="5.0" spread="2.9"/>
                    <measurement group_id="B3" value="4.8" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.2" spread="14.4"/>
                    <measurement group_id="B2" value="98.9" spread="10.4"/>
                    <measurement group_id="B3" value="98.55" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="3.3"/>
                    <measurement group_id="B2" value="33.3" spread="3.7"/>
                    <measurement group_id="B3" value="33.35" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111" spread="9"/>
                    <measurement group_id="B2" value="110" spread="13"/>
                    <measurement group_id="B3" value="110.5" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="1.0"/>
                    <measurement group_id="B2" value="1.9" spread="0.9"/>
                    <measurement group_id="B3" value="1.9" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="1.2"/>
                    <measurement group_id="B2" value="4.5" spread="0.8"/>
                    <measurement group_id="B3" value="4.55" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Density LIpoprotein cholesterol (HDL-c)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="0.3"/>
                    <measurement group_id="B2" value="1.0" spread="0.2"/>
                    <measurement group_id="B3" value="1.05" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low density lipoprotein cholesterol (LDL-c)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="0.7"/>
                    <measurement group_id="B2" value="2.6" spread="0.5"/>
                    <measurement group_id="B3" value="2.65" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120" spread="8"/>
                    <measurement group_id="B2" value="120" spread="10"/>
                    <measurement group_id="B3" value="120" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81" spread="7"/>
                    <measurement group_id="B2" value="76" spread="8"/>
                    <measurement group_id="B3" value="78.5" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Fat</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="6.6"/>
                    <measurement group_id="B2" value="31.0" spread="2.8"/>
                    <measurement group_id="B3" value="32.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Area under the curve (AUC) glucose</title>
          <description>The area under the curve (AUC) of glucose, (0.5 * glucose (G) 0´ + (G 30´+G 60´ + G 90´) + 0.5 * G 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia.</description>
          <units>mmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="508" spread="87"/>
                    <measurement group_id="B2" value="513" spread="146"/>
                    <measurement group_id="B3" value="511" spread="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Area under the curve (AUC) insulin</title>
          <description>The area under the curve (AUC) of insulin, (0.5 * Insulin (I) 0´ + (I 30´+I 60´ + I 90´) + 0.5 * I 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia.</description>
          <units>pmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285" spread="114"/>
                    <measurement group_id="B2" value="326" spread="181"/>
                    <measurement group_id="B3" value="307" spread="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fasting Glucose</title>
        <description>Fasting glucose will be evaluated at baseline and Day 28 with enzymatic-colorimetric.</description>
        <time_frame>Fasting glucose at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose</title>
          <description>Fasting glucose will be evaluated at baseline and Day 28 with enzymatic-colorimetric.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="0.6"/>
                    <measurement group_id="O2" value="5.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.327</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.635</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postprandial Glucose</title>
        <description>Postprandial glucose will be evaluated at baseline and Day 28 after a oral glucose. tolerance test with enzymatic-colorimetric techniques.</description>
        <time_frame>Postprandial glucose at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Glucose</title>
          <description>Postprandial glucose will be evaluated at baseline and Day 28 after a oral glucose. tolerance test with enzymatic-colorimetric techniques.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="2.1"/>
                    <measurement group_id="O2" value="6.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.380</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.441</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>First Phase of Insulin Secretion</title>
        <description>First phase of insulin secretion will be calculated at baseline and Day 28 with Stumvoll Index.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
        <time_frame>First phase of insulin secretion at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>First Phase of Insulin Secretion</title>
          <description>First phase of insulin secretion will be calculated at baseline and Day 28 with Stumvoll Index.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1602" spread="800"/>
                    <measurement group_id="O2" value="1194" spread="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0515</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.953</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Insulin Secretion</title>
        <description>Total insulin secretion will be calculated at baseline and Day 28 with Insulinogenic Index.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion</description>
        <time_frame>Total insulin secretion at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Insulin Secretion</title>
          <description>Total insulin secretion will be calculated at baseline and Day 28 with Insulinogenic Index.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.29"/>
                    <measurement group_id="O2" value="0.61" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.314</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.594</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity</title>
        <description>Insulin sensitivity will be calculated at baseline and Day 28 with Matsuda Index.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
        <time_frame>Insulin sensitivity at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Insulin sensitivity will be calculated at baseline and Day 28 with Matsuda Index.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.1"/>
                    <measurement group_id="O2" value="4.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.767</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.779</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) Glucose</title>
        <description>Area under the curve of glucose measured at baseline and Day 28. The area under the curve (AUC) of glucose, (0.5 * glucose (G) 0´ + (G 30´+G 60´ + G 90´) + 0.5 * G 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia.</description>
        <time_frame>AUC at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Glucose</title>
          <description>Area under the curve of glucose measured at baseline and Day 28. The area under the curve (AUC) of glucose, (0.5 * glucose (G) 0´ + (G 30´+G 60´ + G 90´) + 0.5 * G 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia.</description>
          <units>mmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503" spread="137"/>
                    <measurement group_id="O2" value="522" spread="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.859</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.767</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) Insulin</title>
        <description>Area under the curve of insulin measured at baseline and Day 28. The Area Under the Curve (AUC) of insulin, (0.5 * Insulin (I) 0´ + (I 30´+I 60´ + I 90´) + 0.5 * I 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia.</description>
        <time_frame>AUC at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Insulin</title>
          <description>Area under the curve of insulin measured at baseline and Day 28. The Area Under the Curve (AUC) of insulin, (0.5 * Insulin (I) 0´ + (I 30´+I 60´ + I 90´) + 0.5 * I 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia.</description>
          <units>pmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291" spread="160"/>
                    <measurement group_id="O2" value="262" spread="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.374</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.953</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight</title>
        <description>The body weight will be measured at baseline and Day 28 by Electrical bioimpedance.</description>
        <time_frame>Body Weight at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight</title>
          <description>The body weight will be measured at baseline and Day 28 by Electrical bioimpedance.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" spread="14.4"/>
                    <measurement group_id="O2" value="98.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.594</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>The Body Mass Index will be measured at baseline and Day 28 by Quetelet Index Formula.</description>
        <time_frame>Body Mass Index at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>The Body Mass Index will be measured at baseline and Day 28 by Quetelet Index Formula.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="3.3"/>
                    <measurement group_id="O2" value="33.1" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.594</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.086</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference</title>
        <description>Waist circumference was evaluated at baseline and at Day 28 with a flexible tape.</description>
        <time_frame>Waist circumference at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference</title>
          <description>Waist circumference was evaluated at baseline and at Day 28 with a flexible tape.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="9"/>
                    <measurement group_id="O2" value="112" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.285</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.854</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <description>Triglycerides levels will be evaluated at baseline and Day 28 with enzymatic-colorimetric techniques.</description>
        <time_frame>Triglycerides levels at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>Triglycerides levels will be evaluated at baseline and Day 28 with enzymatic-colorimetric techniques.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.9"/>
                    <measurement group_id="O2" value="2.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.374</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.263</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol</title>
        <description>Total cholesterol levels will be evaluated at baseline and Day 28 with enzymatic-colorimetric techniques.</description>
        <time_frame>Total cholesterol levels at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <description>Total cholesterol levels will be evaluated at baseline and Day 28 with enzymatic-colorimetric techniques.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.9"/>
                    <measurement group_id="O2" value="4.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.859</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.374</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein Cholesterol (HDL-c)</title>
        <description>High density lipoprotein cholesterol (HDL-c) levels will be evaluated at baseline and Day 28 with enzymatic-colorimetric techniques.</description>
        <time_frame>HDL-c levels at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein Cholesterol (HDL-c)</title>
          <description>High density lipoprotein cholesterol (HDL-c) levels will be evaluated at baseline and Day 28 with enzymatic-colorimetric techniques.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.2"/>
                    <measurement group_id="O2" value="1.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.722</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.953</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Density Lipoprotein Cholesterol (LDL-c)</title>
        <description>Low density lipoprotein cholesterol (LDL-c) levels will be evaluated at baseline and Day 28 with Friedewald formula.</description>
        <time_frame>LDL-c levels at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoprotein Cholesterol (LDL-c)</title>
          <description>Low density lipoprotein cholesterol (LDL-c) levels will be evaluated at baseline and Day 28 with Friedewald formula.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.5"/>
                    <measurement group_id="O2" value="2.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.260</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.314</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>The systolic blood pressure was evaluated at baseline and Day 28 with a digital sphygmomanometer.</description>
        <time_frame>Systolic Blood Pressure at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>The systolic blood pressure was evaluated at baseline and Day 28 with a digital sphygmomanometer.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="6"/>
                    <measurement group_id="O2" value="115" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.952</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <time_frame>Diastolic Blood Pressure at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" spread="6"/>
                    <measurement group_id="O2" value="73" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Fat</title>
        <description>The body fat will be measured at baseline and Day 28 by Electrical bioimpedance in %</description>
        <time_frame>Body fat at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Fat</title>
          <description>The body fat will be measured at baseline and Day 28 by Electrical bioimpedance in %</description>
          <units>percentage of fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="3.3"/>
                    <measurement group_id="O2" value="33.1" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.374</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study, an average of 28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tadalafil</title>
          <description>Tadalafil capsules&#xD;
Tadalafil: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Calcined magnesia capsules&#xD;
Placebo: Calcined magnesia capsules: one per day, at night, during 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DR. MANUEL GONZALEZ ORTIZ</name_or_title>
      <organization>INSTITUTO DE TERAPEUTICA EXPERIMENTAL Y CLINICA, UNIVERSITY OF GUADALAJARA</organization>
      <phone>+52 3310585200 ext 34212</phone>
      <email>uiec@prodigy.net.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

